Literature DB >> 26169861

Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.

Brent A Neuschwander-Tetri1, Mark L Van Natta2, James Tonascia2, Elizabeth M Brunt3, David E Kleiner4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26169861     DOI： 10.1016/S0140-6736(15)61200-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.

Authors:  Geula Hanin; Nadav Yayon; Yonat Tzur; Rotem Haviv; Estelle R Bennett; Shiran Udi; Yoganathan R Krishnamoorthy; Eleni Kotsiliti; Rivka Zangen; Ben Efron; Joseph Tam; Orit Pappo; Eyal Shteyer; Eli Pikarsky; Mathias Heikenwalder; David S Greenberg; Hermona Soreq
Journal:  Gut       Date:  2017-04-05       Impact factor: 23.059

2.  NAFLD and cardiovascular disease.

Authors:  Elisabete Martins; Ana Oliveira
Journal:  Porto Biomed J       Date:  2018-07-18

Review 3.  Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.

Authors:  Clarissa Berardo; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Mariapia Vairetti; Andrea Ferrigno
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

Review 4.  Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.

Authors:  Ryan D Welch; Cyrielle Billon; McKenna Losby; Gonzalo Bedia-Diaz; Yuanying Fang; Amer Avdagic; Bahaa Elgendy; Thomas P Burris; Kristine Griffett
Journal:  Metabolites       Date:  2022-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.